Short answer
MIMEDX GROUP, INC. (MDXG) filed its Q3 2026 10-Q quarterly report on Oct 28, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $62M (down 45.2% year over year) with net income of −$9M.
Q3 2026 key financials · XBRL
- Revenue
- $62M
- −45.2% YoY · −3.2% QoQ
- Net income
- −$9M
- −151.8% YoY · +41.5% QoQ
- Operating margin
- -18.8%
- Gross margin
- 79.8%
- EPS (diluted)
- −$0.06
- −154.5% YoY · +40.0% QoQ
Source: XBRL data from the MIMEDX GROUP, INC. (MDXG) Q3 2026 10-Q on SEC EDGAR. USD.
MIMEDX GROUP, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $62.3M, down 45.2% YoY from $113.7M
- Gross margin 79.8% vs 83.5% YoY, pressured by Wound pricing and unfavorable mix
- Best segment Surgical revenue $40.0M, up 9.1%; worst Wound revenue $22.3M, down 71.0%
- Net cash $120.8M, up $2M sequentially; operating cash used $4.2M through nine months
- Near-term headwinds: Medicare reimbursement changes and FTC Second Request delaying Sanara acquisition clearance
Risk Factors
- New regulatory risk: FTC Second Request received October 15, 2026, potentially extending HSR waiting period 30 days after substantial compliance
- New transaction risk: Sanara acquisition could face FTC-imposed conditions, restrictions, or prevention, reducing anticipated benefits
- New financing risk: Hayfin Term Loan availability depends on commitment conditions, with alternative financing potentially costlier
- New leverage risk: Expected Hayfin Term Loan may increase debt service and restrict additional borrowing, investments, dividends, and asset sales
- New operational risk: Acquisition-related review and integration could divert management resources and disrupt employees, customers, and business relationships
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MIMEDX GROUP, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.